Topiramate, pseudotumor cerebri, weight-loss and glaucoma: An ophthalmologic perspective

Patrick Alore; Walter Jay; Mícheál Macken

doi:10.1080/08820530500509325

Topiramate, pseudotumor cerebri, weight-loss and glaucoma: An ophthalmologic perspective

Patrick Alore, Walter Jay, Mícheál Macken^*

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Short survey

22 Scopus citations

Abstract

Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.

Original language	English (US)
Pages (from-to)	15-17
Number of pages	3
Journal	Seminars in Ophthalmology
Volume	21
Issue number	1
DOIs	https://doi.org/10.1080/08820530500509325
Publication status	Published - Jan 1 2006

Fingerprint

Keywords

Glaucoma
Pseudotumor cerebri
Topiramate
Weight loss

ASJC Scopus subject areas

Ophthalmology

Cite this

Alore, P., Jay, W., & Macken, M. (2006). Topiramate, pseudotumor cerebri, weight-loss and glaucoma: An ophthalmologic perspective. Seminars in Ophthalmology, 21(1), 15-17. https://doi.org/10.1080/08820530500509325

@article{3d5a51823e3e408a9201364a1394bd2a,

title = "Topiramate, pseudotumor cerebri, weight-loss and glaucoma: An ophthalmologic perspective",

abstract = "Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.",

keywords = "Glaucoma, Pseudotumor cerebri, Topiramate, Weight loss",

author = "Patrick Alore and Walter Jay and M{\'i}che{\'a}l Macken",

year = "2006",

month = "1",

day = "1",

doi = "10.1080/08820530500509325",

language = "English (US)",

volume = "21",

pages = "15--17",

journal = "Seminars in Ophthalmology",

issn = "0882-0538",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Topiramate, pseudotumor cerebri, weight-loss and glaucoma

T2 - An ophthalmologic perspective

AU - Alore, Patrick

AU - Jay, Walter

AU - Macken, Mícheál

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.

AB - Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.

KW - Glaucoma

KW - Pseudotumor cerebri

KW - Topiramate

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=33646928897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646928897&partnerID=8YFLogxK

U2 - 10.1080/08820530500509325

DO - 10.1080/08820530500509325

M3 - Short survey

C2 - 16517439

AN - SCOPUS:33646928897

VL - 21

SP - 15

EP - 17

JO - Seminars in Ophthalmology

JF - Seminars in Ophthalmology

SN - 0882-0538

IS - 1

ER -

Access to Document

10.1080/08820530500509325